Key result
Dabigatran interruption shows similar pocket hematoma risk to warfarin in AF patients undergoing CIED surgery.
Why the study?
Peri-operative anticoagulation management, bleeding, and thrombotic events in AF patients undergoing CIED surgery treated with dabigatran versus warfarin were compared to address clinical uncertainty.
Does short-term dabigatran interruption reduce peri-operative pocket hematomas and thrombotic events compared to warfarin interruption in AF patients undergoing CIED surgery?
Cohort (n=611)
Yes
Does short-term dabigatran interruption reduce peri-operative pocket hematomas and thrombotic events compared to warfarin interruption in AF patients undergoing CIED surgery?
Short-term interruption of dabigatran before CIED surgery is associated with similar or lower rates of pocket hematoma compared to warfarin interruption, particularly avoiding the excess bleeding risk seen with heparin bridging.
Answers are grounded in this paper and cite their sources.
Supports consideration of interrupted dabigatran as alternative to warfarin; hypothesis-generating pending randomized data.
AIMS: Cardiac implantable electronic device (CIED) surgery is commonly performed in patients with atrial fibrillation (AF). The current analysis was undertaken to compare peri-operative anticoagulation management, bleeding, and thrombotic events in AF patients treated with dabigatran vs. warfarin. METHODS AND RESULTS: This study included 611 patients treated with dabigatran vs. warfarin who underwent CIED surgery during the RE-LY trial. Among 201 warfarin-treated patients, warfarin was interrupted a median of 144 (inter-quartile range, IQR: 120-216) h, and 37 (18.4%) patients underwent heparin bridging. In dabigatran-treated patients (216 on 110 mg bid and 194 on 150 mg bid), the duration of dabigatran interruption was a median of 96 (IQR: 61-158) h. Pocket hematomas occurred in 9 (2.20%) patients on dabigatran and 8 (3.98%) patients on warfarin (P = 0.218). The occurrence of pocket hematomas was lower with dabigatran compared with warfarin with heparin bridging (RD: -8.62%, 95% CI: -24.15 to - 0.51%, P = 0.034) but not when compared with warfarin with no bridging (P = 0.880). Ischemic stroke occurred in 2 (0.3%) patients; one in the warfarin group (without bridging) and one in the dabigatran 150 mg bid group (P = 0.735). CONCLUSION: In patients treated with dabigatran undergoing CIED surgery, interruption of dabigatran is associated with similar or lower incidence of pocket hematoma, when compared with warfarin interruption without or with heparin bridging, respectively. Whether uninterrupted dabigatran can reduce pocket hematoma or ischemic stroke remains to be evaluated.
No takes yet. Share an insight, caveat, or question.
Essebag et al. (2017) conducted a cohort in Atrial fibrillation undergoing cardiac implantable electronic device (CIED) surgery (n=611). Dabigatran interruption vs. Warfarin interruption (with or without heparin bridging) was evaluated on Pocket hematomas (p=0.218). In patients with atrial fibrillation undergoing CIED surgery, dabigatran interruption was associated with a similar rate of pocket hematomas compared to warfarin overall.
Synapse has enriched 10 related papers. Consider them for comparative context: